Cytyc Pays 10-Times Sales For Proxima, Breast Cancer Therapy Market Entry
This article was originally published in The Gray Sheet
Executive Summary
Cytyc likely will divest Proxima Therapeutics' GliaSite brain tumor radiation therapy system after acquiring the company for its MammoSite breast cancer system under a $160 mil. deal Feb. 9